STAT5 is a crucial downstream effector of Bcr-Abl and JAK2V617F, the major transforming agents in Philadelphia-positive (Ph+) CML and Philadelphia-negative (Ph-) myeloproliferative neoplasms respectively. This evidence concerns the gene STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive.